Timothy J. Schroeder, founder and CEO of CTI Clinical Trial and Consulting Services (CTI), will present at two industry meetings this week.
Covington-based CTI is a multi-national, privately held, full-service contract research organization
Schroeder will present at the Bourne Partners 9th Annual Global Healthcare Executive Summit and the Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mesa on October 1 and October 2, respectively.
The Bourne Partners 9th annual Global Healthcare Executive Summit will take place in Charlotte, North Carolina, October 1.
Schroeder will present a featured case study to the attendees titled, “Establishing a World Class CRO.” The presentation will focus on lessons learned from CTI’s 20 years of success.
Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC and consumer health sectors focusing on facilitating the efficient movement of capital through the global healthcare sector.
Schroeder has more than 35 years of clinical, academic, and industry experience in global drug and device development programs.
Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995.
The ARM Meeting on the Mesa will take place in Carlsbad, California, from October 2-4.
On October 2, Schroeder will chair a session at the meeting titled, “Cell and Gene Therapy for Neurological Product Indications.”
The session will focus on the state of development and clinical progress for these next-generation durable treatments for CNS conditions.
ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. In addition to speaking at the event, CTI is also a sponsor and regular supporter of ARM and its various meetings.
“We’re honored to be a part of both the Bourne Partners Summit and the Meeting on the Mesa,” said Schroeder. “We are happy to share our experience and lessons learned from the past 20 years in the hopes that we can both help support our peers and further efforts in breakthroughs using cell and gene therapies.”
CTI has associates in North America, Europe, Latin America and Asia-Pacific.
The firm, which in one of the 20 largest CROs in the world, has supported more than 100 drug and device approvals, currently works on behalf of approximately 135 global pharmaceutical and biotechnology companies.
CTI